Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$0.65 USD
-0.01 (-1.84%)
Updated Jun 7, 2024 03:41 PM ET
After-Market: $0.66 +0.01 (1.49%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNSE 0.65 -0.01(-1.84%)
Will SNSE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SNSE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SNSE
Sensei Biotherapeutics Unveils Updated Corporate Presentation
Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Viking Therapeutics (VKTX)
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE) and Omeros (OMER)
Sensei Biotherapeutics resumed with a Buy at Citi
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference